STAT

JANUARY 30, 2024

In response to concerns over multimillion-dollar price tags for new gene therapies for sickle cell disease, the U.S. government on Tuesday announced a long-awaited “access model” designed to blunt the cost that state Medicaid programs would pay for these curative treatments. million and $3.1

124

124

STAT

MARCH 10, 2023

By law, Medicare will have to take a medication’s efficacy and its research and development costs into account when it starts to negotiate drug prices — but recent research shows pharma companies ignore those factors when they pick prices for their products. Continue to STAT+ to read the full story…

87

87

STAT

OCTOBER 27, 2022

Amid sporadic shortages of a drug that is essential in preparing patients for lifesaving, cancer-fighting treatments, one manufacturer has returned to the market — but is selling its medicine for 10 to 20 times the prices offered by the only other companies with available supplies.

Dosage 101

Dosage 101

STAT

JANUARY 6, 2023

Food and Drug Administration has granted accelerated approval to the widely anticipated Alzheimer’s drug from Eisai and Biogen, a key question is the extent to which payers — private and public — will cover the treatment. Such decisions are based on myriad factors, starting with the average $26,500 price tag.

FDA 92

FDA 92

Pharmaceutical Technology

SEPTEMBER 30, 2022

Spark Therapeutics’ Luxturna, indicated for inherited retinal disease (IRD), was the first gene therapy to be approved, in 2017, with a price tag of $850,000 for each eye. bluebird then broke its own pricing record when the $3m Skysona was approved, and now faces the unique challenge of selling the world's two most expensive drugs.

FDA 115

FDA Insurance 115

The Checkup by Singlecare

DECEMBER 8, 2023

We’re here to help you get the best prices at the pharmacy, just like we did for these customers! RELATED: Health insurance statistics 2023 Unfortunately, rising healthcare costs mean higher drug prices and even copays are harder to afford. Keep reading to see some of our favorite reviews from the year.

Insurance 105

Insurance Customer Service Dosage 105

STAT

DECEMBER 12, 2023

The news comes as researchers are still processing the Food and Drug Administration’s landmark approval of two cutting-edge sickle cell therapies, one made by Vertex Pharmaceuticals and CRISPR Therapeutics and the other by Bluebird Bio. These drugs have price tags of $2.2 million and $3.1 million, respectively.

Chemotherapy 111

Chemotherapy Immunization 111

The Checkup by Singlecare

AUGUST 31, 2023

| How to get Mounjaro without insurance Mounjaro (tirzepatide) is a brand-name prescription drug FDA-approved to control blood sugar levels in people with Type 2 diabetes. Mounjaro can only be purchased at a premium price. Mounjaro can only be purchased as a premium-priced brand-name drug. mL of 5 mg/0.5

Insurance 98

Insurance Compounding Insurance Coverage Labelling 98

STAT

MARCH 10, 2023

Enjoy, and see you soon … By law, Medicare will have to take a medication’s efficacy and its research and development costs into account when it starts to negotiate drug prices — but recent research shows pharma companies ignore those factors when they pick prices for their products , STAT explains. Two

63

63

STAT

JANUARY 31, 2024

… Novo Nordisk has begun to increase availability of its blockbuster obesity drug Wegovy for new patients in the U.S. Overall, Novo saw 154% growth in obesity drug revenue in 2023, driven by sales of its older obesity drug Saxenda and the launch of Wegovy in additional countries.

81

81

Pharmaceutical Technology

FEBRUARY 10, 2023

On November 22, 2022, the FDA approved CSL Behring’s Hemgenix (etranacogene dezaparvovec), the first gene therapy treatment for hemophilia B, with a staggering manufacturer price of $3.5 million, according to GlobalData’s Price Intelligence (POLI), making it the most expensive drug in the world.

FDA 105

FDA 105

pharmaphorum

DECEMBER 24, 2021

The anti-amyloid drug, which also claimed a breakthrough tag from the FDA in July, is being developed for the treatment of early-stage Alzheimer’s disease. The $56,000-a-year price tag for the drug, which has now been cut in half in the US, also hasn’t helped the drugmakers make a case for Aduhelm with US payers.

FDA 109

FDA 109

STAT

OCTOBER 6, 2022

… Multimillion-dollar prices for a rival’s treatments with the potential to cure rare diseases are “in the right ballpark,” according to Stuart Arbuckle, chief operating officer at Vertex Pharmaceuticals, which is preparing to market its own treatment for sickle-cell disease , Bloomberg News tells us. Even

69

69

STAT

AUGUST 2, 2023

… So many people have turned to drugs used for weight loss that some employers are cutting off insurance coverage to head off climbing bills , The Wall Street Journal reports.  The reimbursement cuts, along with restrictions that other employers are implementing, mark the financial downside of the drugs’ medical triumph.

Insurance Coverage 69

Insurance Coverage Insurance 69

Pharmaceutical Technology

MAY 19, 2023

DMTs for MS have a high price tag, particularly in the US. According to GlobalData’s recent Multiple Sclerosis: Seven-Market Drug Forecast and Market Analysis to 2030 – Update report, which identified 19 DMTs marketed for MS in the US, the average annual cost of therapy increased by 9% between 2020 and 2022.

98

98

The Checkup by Singlecare

DECEMBER 20, 2022

Oxybutynin is an antispasmodic and anticholinergic drug, which relaxes smooth muscles in the bladder by blocking acetylcholine, the chemical that signals muscles to contract. . Immediate-release oxybutynin tablets are lower-priced generics, but extended-release oxybutynin chloride ER usually costs twice as much. SingleCare price.

Insurance 52

Insurance Insurance Coverage Dosage 52

pharmaphorum

JUNE 8, 2021

The FDA “has failed in its responsibility to protect patients and families from unproven treatments with known harms” in approving Biogen’s Alzheimer’s disease drug Aduhelm. It said the drug was the first to treat the underlying mechanism in Alzheimer’s rather than addressing symptoms.

FDA 98

FDA Labelling 98

pharmaphorum

AUGUST 21, 2022

There is still a pressing need for antidepressant therapies that can start to work more quickly than current tricyclic or selective serotonin reuptake inhibitor drugs can take weeks to elevate mood, placing severely affected patients at risk of self harm before they kick in. Photo by Sydney Sims on Unsplash.

FDA 91

FDA Labelling 91

pharmaphorum

NOVEMBER 19, 2020

Novartis/Genentech’s eye drug Lucentis could be the next big blockbuster to face competition from cheaper biosimilars after its US patent expired this year – and Samsung Bioepis and Biogen are closing in after the FDA accepted a filing for their cut-price rival.

FDA 62

FDA Labelling 62

pharmaphorum

APRIL 26, 2021

The initiative was supported by grants from UCB and Pfizer and provided health information in the form of immersive experiences aimed at patients prescribed biologic drugs to treat the disease. The company halted development before it eventually sold its digital health unit back to Eric Careel, co-founder of Withings, the following year.

Hospitals 119

Hospitals 119

The Checkup by Singlecare

DECEMBER 5, 2023

Ozempic became one of the most talked about drugs in 2023. The #ozempic tag on TikTok has amassed over 1 billion views to date. The typical price may run as high as $1,200, but a SingleCare coupon can decrease that price drastically. Xenical or Alli (orlistat): Orlistat is another form of weight loss drug taken orally.

Insurance 105

Insurance Prescription Filling FDA Dosage 105

pharmaphorum

NOVEMBER 19, 2021

The cost-effectiveness agency had turned down Evrysdi (risdiplam) in draft guidance published in June, saying it was too expensive, but after negotiations with Roche has reached a deal that will make the drug available to around 1,500 people in England. million price tag make it is the most expensive treatment ever approved for NHS funding.

92

92

pharmaphorum

OCTOBER 21, 2021

Analysts were predicting sales of Biogen’s recently approved Alzheimer’s therapy Aduhelm may start to gather a little momentum in the third quarter, but the drug seems to be going into reverse. million in sales for the drug in the second quarter. Biogen reported $1.6

Insurance 109

Insurance FDA 109

pharmaphorum

JANUARY 21, 2022

“It has become clear that the medicines of the 20 th century, the so-called blockbuster era, are gradually being replaced by drugs designed for smaller groups, specific indication, and even for individual patients,” said Jo De C**k, CEO of Belgium’s National Institute for Health and Disability Insurance. WHO is OMI?

Insurance 52

Insurance Vaccines 52

Pharmaceutical Technology

DECEMBER 15, 2022

In an expanded version of the sales forecast from GlobalData’s June 2022 publication, Cardiomyopathies: Global Drug Forecast and Market Analysis , the global cardiomyopathies market is expected to grow from $3.07bn last year to $9.63bn in 2031. The second highest contributing market is APAC, generating 33.2%

52

52

pharmaphorum

APRIL 14, 2022

million price tag. ICER’s assessment is still at the draft stage and could be changed after an ongoing comment period, but will be welcomed by bluebird and other gene therapy developers as they try to set a price for their one-shot treatments that will be accepted by payers.

FDA 62

FDA 62

pharmaphorum

JANUARY 9, 2023

” Zolgensma is one of the most expensive therapies available, with a price tag of around $2.1 ” NHS England said the temporary change in eligibility – which ties in with NICE guidance – has been implemented as there are two other disease-modifying drugs available on the NHS for the treatment of SMA.

114

114

pharmaphorum

JUNE 12, 2022

Beti-cel has already been approved for marketing in Europe as Zynteglo, with a price tag of around $1.8 million price tag, saying its ability to help patients reach sustained transfusion independence justified its high price.

FDA 57

FDA 57

Pharmaceutical Technology

JUNE 29, 2022

The US Food and Drug Administration (FDA) put a high-profile bluebird bio trial for sickle cell disease on partial clinical hold, and advisory panels deliberated over decisions involving gene therapies for amyotrophic lateral sclerosis (ALS), cerebral adrenoleukodystrophy (CALD), and beta-thalassemia.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies FDA 98

pharmaphorum

MAY 17, 2021

Empaveli’s label covers treatment-naïve PNH patients as well as those who want to switch from Soliris or Ultomiris, and is based on the phase 3 PEGASUS trial in 80 patients which compared the drug to Soliris over a 16-week period. The post Apellis set to take on Alexion as FDA clears PNH drug Empaveli appeared first on.

FDA 52

FDA Labelling Vaccines 52

pharmaphorum

DECEMBER 12, 2022

Updated results from the ADVANCE IV study of Vyvgart (efgartigimod alfa) showed that more than half of patients with ITP treated with Argenx’ drug showed an improvement in platelet counts, which are dramatically reduced in the disorder. After 24 weeks, 21.8%

Immunization 52

Immunization Labelling FDA 52

Pharmaceutical Technology

JULY 14, 2022

The commercial investment required to research and develop an innovative drug, prove its safety and efficacy, and bring it to market is staggering. Most famously, the US passed its Orphan Drug Act in 1983, providing innovators with financial motivation to develop orphan drugs and meet the needs of these forgotten patients.

Pharmaceutical Companies 59

Pharmaceutical Companies Pharmaceutical Companies Hospitals 59

pharmaphorum

JUNE 2, 2021

NICE has rejected routine NHS funding for Roche’s Evrysdi (risdiplam) for spinal muscular atrophy drug in draft guidance, a decision which doesn’t come as a surprise to patient association SMA UK. Comments can be submitted until 23 June. — Spinal Muscular Atrophy UK (@SMA_UK_) June 2, 2021.

Documentation 52

Documentation Communication 52

pharmaphorum

MARCH 23, 2022

Argenx only recently scored FDA approval for its intravenous anti-neonatal FC receptor (FcRn) antibody Vyvgart for generalised myasthenia gravis (gMG), but is already looking to defend its franchise with a new subcutaneous version of the drug.

FDA 52

FDA 52

pharmaphorum

JUNE 2, 2022

R&D into orphan drugs is growing alongside the number of approved treatments, providing treatments for rare diseases that previously did not have any. The price is right. Evaluate Pharma’s recent Orphan Drug Report subtitled its overview of the market ‘Niche no longer.’ It is estimated that between 3.5

Compounding 52

Compounding Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

APRIL 5, 2022

It’s the first treatment for mUM in the EU, as well as the first BiTE drug to treat a solid tumour. The therapy is a bispecific T cell engager (BiTE) molecule, consisting of a soluble TCR targeting gp100 expressed on cancer cells fused to a protein that binds CD3 receptors on lymphocytes. ” Image by Pexels from Pixabay .

Labelling 52

Labelling Chemotherapy Immunization 52

pharmaphorum

NOVEMBER 24, 2022

Both drugs were given on top of standard antidepressants to patients wo had failed a least two earlier treatments. One issue has been the cost of the drug, with health technology assessment agency NICE in the UK and the ICER organisation in the US both concluding its price tag means it is not a cost-effective option for health systems.

Labelling 52

Labelling Hospitals 52